DiaMedica Therapeutics Inc. (DMAC) Tops Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to DiaMedica Therapeutics Inc. (DMAC) Tops Q2 EPS by 2c

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results

August 14, 2023 4:13 PM EDT

Conference Call and Webcast August 15 at 8:00 am Eastern Time / 7:00 am Central Time

Company Resumes ReMEDy2 Clinical Trial after Clinical Hold Lifted Company Completed a $37.5M At-The-Market Private Placement, Cash Runway Into 2026 Company Completed an Additional Safety Cohort of ACEi Patients in its Phase 1C Healthy Volunteer Study

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update... More